Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

tercica, inc. - apomorphine hydrochloride (unii: f39049y068) (apomorphine - unii:n21far7b4s) - apomorphine hydrochloride 30 mg in 3 ml

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apowok solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 30 mg - injection, solution - excipient ingredients: sodium metabisulfite; hydrochloric acid; water for injections - movapo pen is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

max health limited - apomorphine hydrochloride 5 mg/ml - solution for infusion - 5 mg/ml - active: apomorphine hydrochloride 5 mg/ml excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection - apomorphine is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - apomorphine hydrochloride hemihydrate -

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

archimedes pharma uk limited - apomorphine hydrochloride - solution for inj/inf - 10 mg/ml

Νέα Ζηλανδία - Αγγλικά - Ministry for Primary Industries

zoetis new zealand limited - apomorphine hydrochloride - apomorphine hydrochloride 208.3 g/kg - antidote

Βέλγιο - Αγγλικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - apomorphine hydrochloride 5 mg/ml - solution for injection/infusion - 5 mg/ml - apomorphine hydrochloride 5 mg/ml - apomorphine

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

acravet ltd - apomorphine hydrochloride - solution for injection - 3 mg/ml - neurological preparations - canine - neurological preparations